Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab (STAMP) Trial

September 22, 2020

The STAMP trial is currently recruiting participants at sites all across the country.

This phase III trial studies how well pembrolizumab works compared to standard of care observation in treating patients with stage I-III Merkel cell cancer that has been completely removed by surgery (resected). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

For more information, click here.